1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Encephalitis - Pipeline Review, H1 2017

Encephalitis - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 38 pages

Encephalitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis – Pipeline Review, H1 2017, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 6, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Encephalitis - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalitis - Overview
Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalitis - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
CEL-SCI Corp
Prosetta Biosciences Inc
Sage Therapeutics Inc
Encephalitis - Drug Profiles
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
miltefosine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
PAV-645 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Polyglactin 370 for Acute Encephalitis Syndrome - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SAGE-718 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VY-OZ - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Encephalitis - Dormant Projects
Encephalitis - Product Development Milestones
Featured News and Press Releases
Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
Dec 15, 2015: U.S. Issues Patent on Corifungin
Feb 26, 2013: National Institutes of Health Supports Acea's Research
Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria
Aug 22, 2011: FDA Grants 2nd Orphan drug designation
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Encephalitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Encephalitis - Pipeline by Aeterna Zentaris Inc, H1 2017
Encephalitis - Pipeline by CEL-SCI Corp, H1 2017
Encephalitis - Pipeline by Prosetta Biosciences Inc, H1 2017
Encephalitis - Pipeline by Sage Therapeutics Inc, H1 2017
Encephalitis - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Encephalitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.